Item 9 Labs Corp Appoints Andrew Bowden to Board of Directors
SCOTTSDALE, Ariz., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, recently announced the appointment of Andrew Bowden, co-founder and CEO of Bowden Investment Group, to its Board of Directors.
Bowden Investment Group entered into a partnership with Item 9 Labs in October 2018, making a USD $7.7 million investment. The capital will support the planned geographic expansion of the Company in Arizona and Nevada as it advances its cannabis industry presence.
“The partnership with Item 9 Labs was a natural progression for Bowden Investment Group, as we focus on new technologies and cutting-edge investment strategies,” stated Bowden, who also witnessed first-hand the benefits of medical cannabis while his mother underwent breast cancer treatment.
Bowden co-founded Bowden Investment Group, formerly VIRIDIS Group, with his father Doug Bowden in 2013. The family-owned investment company is renowned for building the first 100% sustainable apartment complex in Scottsdale, Arizona. In addition to green construction, real estate, and software, Bowden Investment Group has interests in fitness and health.
“Andrew shares our vision for an environmentally friendly future and passion for wellness. We are excited to have him join our Board,” stated Sara Gullickson, CEO of Item 9 Labs.
Item 9 Labs develops medical cannabis products with organic practices for whole body health. For information visit Item9LabsCorp.com.
About Bowden Investment Group:Bowden Investment Group is a family-owned Investment Company with experience in real estate investment and environmentally sustainable development as well as software, health and fitness. Bowden Investment Group prides itself in having an open minded team and a diversified portfolio. An active equity company, Bowden Investment Group provides funding necessary to launch projects and an engaged team that is hands on with each venture on a daily basis.
About Item 9 Labs Corp.:Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact: Neko CatanzaroProven Media Neko@provenmediaservices.com 401-484-4980
Investor Contact: Jeffrey Rassas Item 9 Labs Corp. Jeffrey@item9labs.com (602) 463-4246